<p>InspireMD, Inc.（紐約證券交易所代碼：NSPR - 獲取免費報告）週二的盤中交易中，股價上漲了 2%。該公司的股價最高達到 2.05 美元，最後交易價格為 2.00 美元。在交易中，共成交了 62,647 股，較平均交易量 109,290 股下降了 43%。該股票此前收盤價為 1.96 美元。</p>
<h2>InspireMD 股價上漲 2.0%</h2>
<p>該股票的 50 日移動平均線為 2.22 美元，200 日移動平均線為 2.35 美元。該股票的市值為 8474 萬美元，市盈率為-2.67，貝塔值為 0.64。</p>
<h2>對 InspireMD 的對沖基金看法</h2>
<p>對沖基金最近對該公司的持倉進行了調整。Huntleigh Advisors Inc.在第二季度將其在 InspireMD 的持倉增加了 5.8%。Huntleigh Advisors Inc.目前擁有 124,228 股該公司的股票，價值 282,000 美元，在此期間又購買了 6,821 股。Raymond James Financial Inc.在第二季度將其在 InspireMD 的股份增加了 28.9%。Raymond James Financial Inc.目前擁有 44,604 股該公司的股票，價值 101,000 美元，在上個季度又購買了 10,000 股。Citadel Advisors LLC 在第三季度將其在 InspireMD 的持倉增加了 45.0%。Citadel Advisors LLC 目前擁有 37,954 股該公司的股票，價值 91,000 美元，在此期間又購買了 11,778 股。Rosalind Advisors Inc.在第二季度將其在 InspireMD 的持倉增加了 0.6%。Rosalind Advisors Inc.目前擁有 2,289,099 股該公司的股票，價值 5,196,000 美元，在此期間又購買了 14,109 股。最後，XTX Topco Ltd 在第一季度獲得了 InspireMD 的新股份，價值約 38,000 美元。對沖基金和其他機構投資者持有該公司 44.78% 的股票。</p>
<h2>InspireMD 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>InspireMD, Inc.是一家醫療設備公司，專注於 MicroNet 支架平台技術的開發和商業化，旨在治療歐洲、拉丁美洲、中東和亞太地區的血管和冠狀動脈疾病。該公司提供 CGuard 頸動脈栓塞預防系統（EPS），用於頸動脈應用；CGuard Prime 支架系統，一種網狀覆蓋的自擴張頸動脈支架；以及 SwitchGuard NPS，一種非侵入性的經頸動脈再血管化設備；同時還治療伴有串聯病變的急性中風。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 InspireMD</li>
<li>3 只超市股票證明它們仍然是必需品</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>寶潔公司（NYSE: PG）在不穩定的指引後回落</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>能源和石油股票解析</li>
<li>標普 500 指數在 12 月會反彈嗎？這 3 個信號指向大幅波動</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 InspireMD 嗎？</h2>
<p>在考慮 InspireMD 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 InspireMD 並不在名單上。</p>
<p>雖然 InspireMD 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

NSPR

<p>InspireMD 的股票（NYSE:NSPR）在午盤交易中上漲了 2%，達到了 2.05 美元的高點。儘管有所上漲，但交易量較平均水平下降了 43%。對沖基金已調整其頭寸，Huntleigh Advisors、Raymond James Financial 和 Citadel Advisors 等公司顯著增持。InspireMD 專注於用於血管疾病的 MicroNet 支架技術。雖然該股票獲得了買入評級，但頂級分析師建議其他股票可能是更好的投資選擇</p>

<p>InspireMD, Inc. (NYSE:NSPR - Get Free Report)'s stock price shot up 2% during mid-day trading on Tuesday . The company traded as high as $2.05 and last traded at $2.00. 62,647 shares traded hands during trading, a decline of 43% from the average session volume of 109,290 shares. The stock had previously closed at $1.96.</p>
<div class="lb-trans"><p>InspireMD, Inc.（紐約證券交易所代碼：NSPR - 獲取免費報告）週二的盤中交易中，股價上漲了 2%。該公司的股價最高達到 2.05 美元，最後交易價格為 2.00 美元。在交易中，共成交了 62,647 股，較平均交易量 109,290 股下降了 43%。該股票此前收盤價為 1.96 美元。</p>
</div><h2>InspireMD Trading Up 2.0%</h2>
<div class="lb-trans"><h2>InspireMD 股價上漲 2.0%</h2>
</div><p>The stock's 50-day moving average is $2.22 and its 200-day moving average is $2.35. The stock has a market cap of $84.74 million, a price-to-earnings ratio of -2.67 and a beta of 0.64.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 2.22 美元，200 日移動平均線為 2.35 美元。該股票的市值為 8474 萬美元，市盈率為-2.67，貝塔值為 0.64。</p>
</div><h2>Hedge Funds Weigh In On InspireMD</h2>
<div class="lb-trans"><h2>對 InspireMD 的對沖基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Huntleigh Advisors Inc. boosted its position in InspireMD by 5.8% during the 2nd quarter. Huntleigh Advisors Inc. now owns 124,228 shares of the company's stock worth $282,000 after purchasing an additional 6,821 shares during the period. Raymond James Financial Inc. lifted its stake in shares of InspireMD by 28.9% during the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company's stock worth $101,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company's stock worth $91,000 after buying an additional 11,778 shares during the period. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company's stock worth $5,196,000 after buying an additional 14,109 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of InspireMD in the first quarter valued at about $38,000. Hedge funds and other institutional investors own 44.78% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。Huntleigh Advisors Inc.在第二季度將其在 InspireMD 的持倉增加了 5.8%。Huntleigh Advisors Inc.目前擁有 124,228 股該公司的股票，價值 282,000 美元，在此期間又購買了 6,821 股。Raymond James Financial Inc.在第二季度將其在 InspireMD 的股份增加了 28.9%。Raymond James Financial Inc.目前擁有 44,604 股該公司的股票，價值 101,000 美元，在上個季度又購買了 10,000 股。Citadel Advisors LLC 在第三季度將其在 InspireMD 的持倉增加了 45.0%。Citadel Advisors LLC 目前擁有 37,954 股該公司的股票，價值 91,000 美元，在此期間又購買了 11,778 股。Rosalind Advisors Inc.在第二季度將其在 InspireMD 的持倉增加了 0.6%。Rosalind Advisors Inc.目前擁有 2,289,099 股該公司的股票，價值 5,196,000 美元，在此期間又購買了 14,109 股。最後，XTX Topco Ltd 在第一季度獲得了 InspireMD 的新股份，價值約 38,000 美元。對沖基金和其他機構投資者持有該公司 44.78% 的股票。</p>
</div><h2>InspireMD Company Profile</h2>
<div class="lb-trans"><h2>InspireMD 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.</p>
<div class="lb-trans"><p>InspireMD, Inc.是一家醫療設備公司，專注於 MicroNet 支架平台技術的開發和商業化，旨在治療歐洲、拉丁美洲、中東和亞太地區的血管和冠狀動脈疾病。該公司提供 CGuard 頸動脈栓塞預防系統（EPS），用於頸動脈應用；CGuard Prime 支架系統，一種網狀覆蓋的自擴張頸動脈支架；以及 SwitchGuard NPS，一種非侵入性的經頸動脈再血管化設備；同時還治療伴有串聯病變的急性中風。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than InspireMD</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
<li>Energy and Oil Stocks Explained</li>
<li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 InspireMD</li>
<li>3 只超市股票證明它們仍然是必需品</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>寶潔公司（NYSE: PG）在不穩定的指引後回落</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>能源和石油股票解析</li>
<li>標普 500 指數在 12 月會反彈嗎？這 3 個信號指向大幅波動</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InspireMD Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 InspireMD 嗎？</h2>
</div><p>Before you consider InspireMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 InspireMD 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 InspireMD 並不在名單上。</p>
</div><p>While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 InspireMD 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

InspireMD（NYSE:NSPR）股價上漲 2% - 你是否應該購買？